From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Interview with Stephanie Giangiuli, PharmD, BCOP: IV Therapies and Side Effect Management in HR+ HER2- Breast Cancer

Brain Metastases in HR+ HER2- Breast Cancer

Introduction to HR+ HER2- Breast Cancer

Welcome to the new HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Christine McGinn, MSN, APRN, ACNP-BC Oncology Nurse Practitioner Lifespan Cancer Institute	Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA System Manager, Oncology & Infusion Pharmacy Services PGY2 Oncology Residency Program Director, UCHealth Memorial Hospital

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Clinical Management of Patients Taking Abemaciclib

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Oral Chemotherapy Education

Cancer Medicine

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer

International Immunopharmacology

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer

Current Medical Research and Opinion

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

ESMO Open

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

Translational Oncology

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer

Frontiers in Immunology

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

American Journal of Clinical Oncology

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

JHEP Reports

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment

npj Breast Cancer

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer